SynthesisFrontiers in endocrinology2025
Exploring the potential association and experimental validation of disrupted circadian rhythms with polycystic ovary syndrome via meta-analysis and bioinformatics: a possible pathogenic mechanism.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polycystic ovary syndrome (PCOS) has been extensively studied as a common female endocrine disease. In recent years, the relationship between circadian rhythm and PCOS has gradually drawn attention, although the precise nature of this connection remains unclear. The aim of this study was to explore further links between circadian rhythm and PCOS and to identify potential mediators of the pathogenesis of PCOS. Method: We analyzed the available data on PCOS and circadian rhythm disorders. Consequently, we identified potential transcription factors (NPAS2, INSIG1, H3F3B, SCML1) through bioinformatics and verified them in a well-established PCOS mouse model. Results: Luteinizing hormone (LH), testosterone (T), and melatonin (ML) exhibited substantial changes in the PCOS patients compared to healthy controls, with ML serving as a crucial biomarker in circadian rhythms. PCR results from ovarian tissues demonstrated altered expression of circadian core oscillator in the PCOS mouse model, with NPAS2 expression aligning with the bioinformatics analysis trend. We used quercetin (QUE) as a treatment and observed that it improved the disturbed expression of circadian core oscillations. Conclusion: Our research revealed the correlation between circadian rhythm disruptions and PCOS, identified potential targets, and provided unique insights into the pathogenesis of circadian rhythm-related PCOS. The improvement of circadian core oscillations in the QUE group offers a novel strategy for the treatment of PCOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.